MetaCap

Aquestive Therapeutics Inc. (AQST)

NASDAQ: AQSTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.46-0.245 (-6.61%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AQST stock chart

Technical analysis

Key statistics

All statistics
Market cap
$434.88M
EPS (TTM)
-$0.65
52-week range
2.93 – 6.74
Day range
3.41 – 3.65
Volume / Avg
3.35M / 2.41M
Beta
—

52-week range

$2.93$6.74

AQST stock today

Shares of Aquestive Therapeutics (AQST) finished lower on Nov 20 at $3.46, a drop of 6.61% or $0.245 per share, versus the S&P 500's 3.70% decline. Shares are 48.6% below their 52-week high of $6.74, set on Dec 8, 2025 and 18.1% above the 52-week low of $2.93, near the bottom of the past year's range. AQST is down 46.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 39.5%.

Aquestive Therapeutics has posted a net loss over the last twelve months (EPS of -$0.65), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Aquestive Therapeutics

Company profile

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Daniel Barber
Headquarters
Warren, NJ
Employees
147
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Aquestive Therapeutics generated $44.5 million in revenue, down 22.6% from fiscal 2024, its first annual decline since 2022. Aquestive Therapeutics reported a net loss of $83.8 million, compared with a loss of $44.1 million a year earlier. Gross margin was 58.3% (down from 69.0%) and operating margin -159.5%.

Aquestive Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$44.55M$57.56M$50.58M$47.68M$50.83M
Growth-22.61%+13.80%+6.09%-6.20%+10.87%
Net income$-83.78M$-44.14M$-7.87M$-54.41M$-70.54M
EPS (diluted)$-0.78$-0.51$-0.13$-1.12$-1.85

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$9.33+169.65%

  • Strong buy 2
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $6.00High $11.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$-0.13 vs $-0.10
Surprise
-30.00%

AQST news

All AQST news

Aquestive Therapeutics peers

Health Care sector
AQST peer companies
CompanyPrice% ChgMarket capCompare
INDPIndaptus Therapeutics Inc.2.82-9.90%$433.16Mvs AQST
EOLSEvolus Inc.6.52-6.86%$431.55Mvs AQST
CAPRCapricor Therapeutics Inc.7.59+0.80%$441.30Mvs AQST
LYELLyell Immunopharma Inc.13.80+1.62%$441.82Mvs AQST
CTMXCytomX Therapeutics Inc.2.03-0.98%$442.55Mvs AQST
AMRNAmarin Corporation plc10.57-6.13%$444.39Mvs AQST
DMACDiaMedica Therapeutics Inc.8.25+2.87%$445.15Mvs AQST
ARVNArvinas Inc.6.46-4.15%$423.03Mvs AQST

Indexes, lists and sector

Aquestive Therapeutics stock FAQ

What is Aquestive Therapeutics's stock price today?

AQST last traded at $3.46 as of Nov 20, 4:00 PM EST, down 6.61% on the day. Prices are delayed at least 15 minutes.

Who is Aquestive Therapeutics's CEO?

Mr. Daniel Barber is the chief executive officer of Aquestive Therapeutics Inc., which has about 147 employees.

What is the AQST 52-week high?

The 52-week high for AQST is $6.74 and the 52-week low is $2.93. The stock is currently 48.6% below its high.

Compare AQST